Scholar Rock receives fast track designation from the U.S. FDA for apitegromab for the treatment of patients with spinal muscular atrophy

Scholar Rock

24 May 2021 - Builds on Priority Medicines (PRIME) designation recently granted by the EMA recognising the unmet medical needs of patients with spinal muscular atrophy.

Scholar Rock today announced that the U.S. FDA has granted fast track designation for apitegromab, a selective inhibitor of myostatin activation, for the treatment of patients with spinal muscular atrophy.

Read Scholar Rock press release


Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Orphan drug , Fast track